Spanish pharmaceutical industry association Farmaindustria has indicated that it will keep the growth in drug spending at between 6% and 6.5% for 18-20 months compared with the current level of 7%, in return for concessions to the industry, reports the financial daily Cinco Dias.
"We understand the policy of the government is to meet the criteria to bring Spain into the European Union's Maastricht Treaty, and I think that Spain should be among those countries that sign the agreement," said Rafael Juste, president of Farmaindustria. "It is for this reason that Farmaindustria is prepared to make an effort and support the government," he added, but warned that "the government must pay serious attention to the matter, because we cannot make this cut without concessions."
Mr Juste said that the commitment could not be for more than 18-20 months as any longer would be a risk to the industry. This time frame fits that of the European Council, which will decide in the spring of 1998 which countries have met the Maastricht criteria.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze